We propose a model of drug pharmacodynamic response that when integrated with a pharmacokinetic model allows characterization of the temporal aspects of pharmacodynamics as
Whereas pharmacokinetic models allow drug distribution and elimination to be characterized, the ultimate clinical and therapeutic value of a drug depends upon its dynamic effect. A combined model for a drug's pharmacokinetics and pharmacodynamics might therefore provide enhanced insight for both clinician and pharmacologist. There are a number of standard approaches for "pure" pharmacokinetic modeling,28 Regarding pharmacodynamics, Wagner7 has proposed that the well-known Hill equation be used to relate the intensity of pharmacologic effect to the concentration of drug in body fluid:
expressed as a fraction of the maximal effect, 1\, is a pharmacokinetic quantity to which effect is related, usually drug amount or concentration in plasma, A e (50) is a constant giving the value of Ae at 50% effect, and ' Y is a parameter that allows sigmoidicity of the Ae to effect relationship. This model has theoretic 11 and empiric 2 support. In addition, with the appropriate choice of parameters, Equation I can faithfully represent a Michaelis-Menten relationship, is transformable into the logistic function,29 and is appropriate for the mode ling of either agonist or antagonist. 11 This equation has been used recently by Meffin, Winkle, and Blaschke l9 to characterize individual patients' responses (suppression of arrhythmias) to tocainide. Ae was taken to be plasma concentration of drug after chronic dosage, implying an equilibrium between plasma concentration and cardiac site of action.
A similar assumption, that the plasma or another pharmacokinetically identifiable compartment is associated with the pharmacologic effect, is traditionally made in pharmacodynamic modeling,15. 16 but traditional pharmacokinetic models concern themselves with the disposition of mass of drug in the body: any site receiving little mass is not described. Because there is no a priori reason to assume that the active site corresponds, kinetically, with a site receiving a large mass of drug, there is little reason to hope that the kinetics of drug in plasma, or other pharmacokinetically determined site, will parallel those at the active site. Therefore, one may, in general, expect that a given plasma (or other tissue) drug concentration will exhibit a temporally varying quantitative relationship to drug effect.
Galeazzi, Benet, and Sheiner 8 recently evaluated the change of the QT interval on the electrocardiogram after a single rapid intravenous infusion of procainamide in this respect. They found a distinct time lag in the occurrence of effect relative to plasma concentration (Cp). The kinetics of the pharmacologic effect they observed were clearly not the same as the drug concentrations in plasma, nor were they parallel to concentrations in the hypothetical "tissue" compartment of the pharmacokinetic model they used; rather, the kinetics of drug effect were intermediate between them, but happened to be indistinguishable from drug concentration kinetics in saliva.
At steady-state no disequilibrium between various sites is possible, and a constant proportionality between plasma (or tissue) concentrations and active site concentration will obtain. To describe the sensitivity of an individual to a drug, we may therefore attempt to relate drug effect to steady-state plasma concentrations. As the above procainamide example stresses, however, this is insufficient to fully describe pharmacodynamics, as temporal characteristics must also be modeled.
It is the purpose of this paper to present the minimum model that can simultaneously deal with both of these aspects of pharmacodynamics and that can be meshed with most standard pharmacokinetic models to yield a fully integrated model for pharmacokinetics and pharmacodynamics. It is conceptually similar to the model recently used by Dahlstrom and coworkers 5 to describe analgesic response in rats. To present our model, we first describe it and its mathematical form. We then illustrate its use by applying it to some data for the drug d-tubocurarine (dTC). We further illustrate the utility of the model by reanalyzing some previously published dTC data 21 according to our model, and show that use of the model allows us to suggest conclusions somewhat different from those originally made.
Methods
The model. We model the temporal aspects of pharmacodynamics by postulating a hypothetical "effect" compartment, the dynamics of which are adjusted to reflect the temporal dynamics of drug effect. These, of course, depend on certain physical and physiologic processes relating drug in blood to drug at its site of action, and hence to the drug's ultimate pharmacologic effect: perfusion, diffusion, partition, drug-receptor interaction, and the relationship between receptor occupancy and effect. We propose to use Equation I to relate drug effect to the (hypothetical) amount of drug in the effect compartment we define. The plasma concentration of drug is modeled by whatever pharmacokinetic model is necessary to characterize the drug concentration data. The mathematical form of the pharmacokinetic model will usually be a sum of exponentials, often interpretable as arising from a mammillary compartmental model. Under this interpretation, the effect compartment is mode led as an additional compartment linked to the plasma compartment by a first-order process, but which receives negligible actual mass of drug and whose exponential therefore does not enter into the pharmacokinetic solution for the mass of drug in the body. This model is shown in Fig. 1 . There, the effect compartment is shown connected to the central compartment by a first-order rate constant, k te , while drug dissipation from the effect compartment is shown occurring by means of a second first-order rate constant, keo' For the transfer of mass to the effect compartment to be negligible, and hence not influence the Cp against time curve, k te , the rate constant connecting the central compartment to the effect compartment is assumed to be very small relative to the magnitude of the smallest other rate constant of the pharmacokinetic model. Under this assumption, the exact magnitude of k te , as will be seen below, is inconsequential. In contrast, the rate constant for drug removal from the effect compartment, k eo , will precisely characterize the temporal aspects of equilibration between Cp and effect.
The solution for the amount of drug in the effect compartment is the solution to the following differential equation: (2) where Ae is the (hypothetical) amount of drug in the effect compartment, At is the amount of drug in the central compartment, and k te and keo are as previously defined. Note that in Fig. I , because negligible mass of drug transfers to the effect compartment, the subsequent loss of this negligible mass from the effect compartment may conveniently be taken to be to the outside rather than back into the system. If the analytical solution for drug in the central compartment after a bolus dose is given by
where D is dose, and AI and ab i = I,N are constants, then the analytical solution to Equation (2) is:
For an intravenous infusion at rate R, given into compartment I, the solution to Equation 2 while the infusion is going on is:
:\ A,,(t) = kteR 2: (5) i=l and the solution for time t > T where T is the time at which the infusion ends is: (6) where t' = t -T and A~ is Equation 5 divided by k le , evaluated at t = T. Equations 4 to 6 thus provide values for Ae, the amount of drug in the effect compartment.
We will find it more meaningful in the sequel to relate drug effect to the concentration of drug in plasma, rather than to an amount of drug in a hypothetical effect compartment. We can do this by considering that at steady-state there will be a steady-state Cp (Cpss) and a unique corresponding steady-state Ae. We now solve for the Cpss that would give rise to any arbitrary Ae, and will express our model for pharmacodynamics in terms of it, rather than Ae. For the effect compartment (or any other compartment) to reach steady-state, its exit rate constant must be greater than zero, and we therefore assume, without loss of generality, that this is true for k eo . where Z is all the rest of the right-hand sides of Equations 4, 5, or 6 except for k le . Note that k le cancels out of Equation 7 so that, as mentioned, its exact value is of no importance, so long as we assume that it is small enough to be ignored in the pharmacokinetic solution for Cp. The Cpss defined by Equation 7 is the one we have been seeking and may now be used in Equation 1. We therefore have:
where all parameters can be estimated and the three new parameters, introduced for the pharmacodynamic model, are ,)" keo, and Cpss(50), the latter being the Cpss causing 50% maximal effect. The effect equation, Equation 8 , now deals directly in (equivalent) steady-state plasma concentrations for sensitivity, and this aspect of pharmacodynamics is isolated from the kinetic aspects, quantified by the parameter k eo .
In utilizing the model, it is preferable to fit Cp and effect data simultaneously to Equations 3 and 8, respectively. However, if the overall model is adequate for the data, little harm is done if the plasma drug concentration data are first fitted to Equation 3. The effect data can then be fitted to Equation 8 with input information being the observed effect at time t and the (previously estimated) values of the pharmacokinetic constants, Aj, aj, (i = I,N) that characterize Cp at time t.
We note here that when keo takes a very large value (relative to other exponential coefficients of the model) the kinetics of the effect compartment exactly parallel (i.e., are always directly proportional to) those of the compartment driving it, the central compartment, if a mammillary model is considered. In addition, if keo is assigned equal to kil where i = 2, ... N, the rate constant from peripheral compartment i to the central compartment of the mammillary model, the effect compartment kinetics exactly parallel those of drug in compartment i.
The patients. Three different data sets were used to evaluate the proposed model. The first group (group 1) consists of 7 healthy patients aged 21 to 49 years of age, who were undergoing elective surgery. Anesthesia and relaxation for intubation were induced with thiopental 4 mg/kg and succinylcholine 1 mg/kg. Anesthesia was maintained with nitrous oxide (70%): oxygen and halothane at an end-tidal concentration of 0.5 to 0.7%. Ventilation was controlled to maintain pC0 2 between 34 and 40 torr. Esophageal temperature was maintained between 34.5 and 36.0. Twenty minutes after induction, each patient received a rapid intravenous infusion of dTC, 16.8 JLg/kg/min over 10 min, followed immediately by a slower infusion of 1.2 JLg/kg/min maintained until the end of surgery (70 to 240 min). This drug administration protocol resulted in an approximately constant plasma concentration of dTC and degree of paralysis (effect) within 50 to 70 min. Venous blood samples were obtained from the forearm opposite that used to administer dTC. Blood samples for drug analysis were obtained every minute during the initial 10 min rapid infusion, and at 2-min intervals for the first 15 min of the second infusion, after which samples were obtained every 15 min until the end of surgery. A total of 20 to 30 blood samples were obtained per patient.
The effect measurement used was the force of thumb adduction, measured with a Grass (FT 10) force displacement transducer, and recorded on a polygraph. The ulnar nerve was stimulated with a Grass S-44 stimulator through 27-gauge needle electrodes placed at the wrist. Single stimuli of O. 1 msec duration at 0.3 pUlse/sec were used to avoid repetitive nerve excitation. The voltage used was 1.5 times that necessary to elicit supramaximal twitch response. The drug effect was quantified by the degree of paralysis, with 0 effect representing no paralysis and 1.0 representing 100% paralysis. The data from this group are used to demonstrate the plausibility of our model for dTC in normal patients.
The second group (group 2) consisted of 21 patients who received treatment identical to that of group I patients, except for the nature of the maintenance anesthesia. Fourteen patients received morphine (0.3 mg/kg), diazepam (0.3 mg/kg), nitrous oxide (70%): oxygen, whereas 7 patients received halothane end-tidal concentration 1.0% to 1.2% as maintenance anesthesia. These patients represent a separate study evaluating the effects of halothane and morphine anesthesia on dTC dose-response, the details of which will be reported later. Some results from these patients have been included here to better assess the amount of data necessary to characterize the proposed pharmacodynamic model. Group 3 consists of 10 normal (N) patients, with normal serum creatinine, undergoing elective surgery, and 10 patients with chronic endstage renal failure (RF), undergoing renal transplantation. Part of these data have already been reported,21 but were not fitted to the model proposed herein. RF patients were anemic (hemoglobin 6.8 ± 1.5 gm/lOO ml)* and had elevated serum creatinine (IO.l ± 2.3 mg/IOO ml),* in spite of recent dialysis. Anesthesia was induced with nitrous oxide: oxygen and halothane with the trachea intubated without drugs. Anesthesia was maintained with nitrous oxide 'Mean ± SO. Analysis of drug concentrations. dTC concentrations in plasma were analyzed using a radioimmunoassay described by Horowitz and Spector. 12 The coefficient of variation of the assay at 3 different concentrations was 8% with a lower limit of sensitivity of 0.05 JLg/ml. Data analysis. The plasma concentration curves of individual patients in groups 1 and 2 were fitted to a biexponential equation interpreted as a 2-compartment mammillary model. A nonlinear least-squares computer program was used. 20 The resulting pharmacokinetic parameters estimated for each individual were then used in fitting their individual effect data to the pharmacodynamic model proposed. Unit weighting was used in fitting plasma and effect data. The data of the 7 patients in group I were used to examine how well the model could represent their data, and to evaluate more carefully two essential components of our model: whether the kinetics of effect are indistinguishable from those of Cp, and whether the standard Michaelis-Menten model is adequate to describe pharmacodynamics. To answer these questions, one needs to compare the relative goodness of fit of the data to the full model with a model having keo very large, for the first question, or one having y = 1, for the second. Accordingly, the data from group 1 were fitted to the full and the alternative models, and the general linear test was used to evaluate the dif- ference in sum of squares, 23 We also tested whether keo was equal to k21 of the mammillary model interpretation of the biexponential pharmacokinetic model we used, If it were, it would imply identity of the kinetics of drug effect with those of drug in the second or "tissue" compartment. The data from the patients in groups I and 2 were combined to evaluate the amount of data necessary to characterize pharmacodynamics. For the 28 patients, the Cpss(50) estimates from the complete data set for the 70 to 240 min of drug infusion (20 to 30 data points per patient) were compared to the Cpss(50) estimates obtained from a reduced data set of only the first 20 to 25 min of effect data (16 data points per patient), The full set of parameters estimated from the reduced data sets were also used to predict the ultimate steady-state effect expected toward the end of the second infusion so that this prediction and the observed effect could be compared,
The data of group 3 were reanalyzed to see whether our model could shed additional light on their results. Due to the limited data available per patient (7 to 9 data points/patient), estimation of each patient's parameters was not feasible and instead a general maximum likelihood data analysis approach was utilized which directly estimates mean population values of the pharmacokinetic and pharmacodynamic parameters along with their interindividual variability.24, 25 Plasma and effect data were fitted simultaneously to the data of all 20 patients. The plasma data were fitted to a biexponential equation (2-compartment mammillary model) and the effect data, to the proposed model. Because previous reports 10 , 21 have indicated no difference in the pharmacokinetics of dTC in N and RF, except for renal excretion, the baseline model chosen was one in which the only distinction between Nand RF patients was the absence of a renal elimination rate constant in the RF patients.
When comparing an alternative model to the baseline one using a maximum likelihood ap- proach, the difference in log likelihoods of the fits can be compared, just as in the generallinear test sums of squares are compared. The distribution of twice this difference is asymptotically chi-square with degrees of freedom equal to the number of parameters fixed or added in the alternative model relative to the baseline model. Standard errors of parameter estimates were approximated by the data analysis program, or, for derived parameters, by using the covariance matrix of the original parameter estimates and a first-order Taylor series approximation to the variance of the derived parameters. 3 The group mean pharmacokinetic and dynamic parameters of the patients in group 3 were compared to those of group 1 patients (using these standard errors) by t tests with the Bonferroni correction for multiple comparisons. 23 tectable effect requires approximately 5 min. Effect then begins to parallel the plasma concentration curve and peaks approximately 5 min later. Visually, this lag between ep and effect suggests the necessity for the keo parameter of our model. With the dual infusion technique, approximately constant ep and effect were obtained within 45 to 60 min of starting the second infusion. The curves drawn through the points in Fig. 2 represent the predicted ep and effect for the best fit of these data to our model. Inspection reveals excellent agreement between observed and fitted ep and effect. This was equally true for all group I and 2 patients. Table I demonstrates that (1) keo is not very large, and hence effect is not directly proportional at all times to the amount of drug in the central compartment; and (2) 'Y is not equal to I; hence, the more general form of the effect relationship (Equation I) is preferred to that tient in the study. In spite of a large amount of interindividual variability, visual inspection suggests that mean performance is accurately reflected by our model. Table II presents the pharmacodynamic parameter estimates for the patients in groups I and 3. The pharmacokinetic parameter estimates are not presented because they are not of central concern to this paper. There was no statistically significant difference between any corresponding (pharmacokinetic or) dynamic parameter estimates in the two groups. Fig . 5 displays the ability of the model , using only the first 20 to 25 min of data for each patient in group I or 2, to predict the ultimate steady-state effect obtained in that patient. The stippled area represents the regression line plus and minus 2 SD for the predictions of the ultimate steady-state effects using the parameters estimated from the complete data sets. It represents the optimal ability of the model to characterize the data. Using only the reduced data sets causes some reduction of the ability to accurately predict the observed responses. The steady-state responses predicted from analysis of the reduced data set nonetheless correlate well (r = 0 .86) with the observed responses.
Results

Fig
The estimates of Cpss(50) from the reduced data sets are more impressively related to the Cpss(50)'s derived from the complete data sets, as shown in Fig . 6 . The correlation coefficient here is 0.97 . Table III compares the pharmacodynamic parameter estimates of Nand RF patients in group 3. The results suggest that keo alone may be different between Nand RF patients . When both keo and Cpss(50) are evaluated together, there is an interaction, suggesting that both may be different between Nand RF patients . This suggestion that the Cp-effect relationship differs in RF and N patients differs from the previous interpretation of the same data .
1
Discussion
Levy 16 . 17 considered a monoexponential model for Cp and first demonstrated that in this circumstance one could expect the intensity of drug effect to be linearly related to the log dose when effect was in the 20 % to 80% effect range.t 6 • 17 He therefore predicted that after bolus drug administration , effect would decline at a constant rather than an exponential rate, and 'From the X-distribution with I df (for the first 2 lines), or 2 df (for the last line). 2dLL is asymptotically distributed X 2 with these degrees of freedom. empirically verified this for the effect of dTC on hand, head, and diaphragmatic muscle.!.' Gibaldi, Levy, and Hayton 9 extended this model to the mUltiexponential description of plasma concentrations required for dTC. Using the urinary excretion data of Kalow, 14 the plasma data of Cohen, Corbascio, and Fleischi 4 and the dose-twitch recovery data of WaIts and Dillon, 26 Gibaldi, and associates demonstrated a direct correlation between dTC effect and the concentration of drug in the central compartment, modeled as a tri-exponential. 9 Deviations of the predictions of their equations from the observed effects were, however, noticed with small doses of dTC and with measurements of effect made soon after drug administration. It was nonetheless concluded that the "site of action" of dTC was kineticaUy indistinguishable from the central compartment.
The data we have presented (Fig. 2) demonstrate that there is a more adequate characterization of certain pharmacodynamic data for dTC when the kinetics of the drug's effect are separately mode led to account for the temporal displacement between Cp and effect. Indeed, when drug effect was deliberately set proportional to the amount of drug in the central compartment for our data, the data characterization was significantly poorer (Table I ). There are several reasons for this. Gibaldi, Levy, and Hayton 9 used Cp and effect data that were obtained during the phase of recovery of effect after bolus drug administration. Thus, data were gathered during pseudoequilibrium between drug and tissue, and the lag between Cp and drug in tissues (including muscle) was minimized. In contrast, most of our data were gathered during the upstroke and subsequent downstroke of a rapid drug infusion when Cp and effect are expected to be maximally out of phase.
In further evaluating our effect data, we find that we agree with Wagner 27 that the nonlinear relationship described by Equation I provides an adequate description (Table I ). This equation allows for a sigmoid shape for the response curve that is not allowed by the simple Michaelis-Menten model, and Equation I is applicable outside the 20% to 80% effect range to which the log concentration relationship proposed by Levy!6 is limited. The ability to measure and predict in the 9S% to 100% effect range is especially important for muscle relaxants, since it has been demonstrated that adequate muscle paralysis for abdominal incision requires this degree of paralysis.! Indeed, much of the group 3 data we analyzed fell in this extreme range (see Fig. 4 ).
As demonstrated in Figs. 2 to 4, it is possible to accurately characterize the relationship between dTC, Cp, and effect with our model. Excellent individual fits are obtained in group I and 2 patients when the model is maximally "stressed": i.e., Cp and effect vary rapidly. The less extreme (in this sense) data of group 3 patients is also well characterized by the proposed model, when analyzed with a general data analysis technique designed to handle the reduced amount of data per individual available for this group. The estimates of the parameters characterizing drug effect for our model do not differ significantly between group I and 3 patients. Whereas the model can deal with responses close to maximal, such data do not contribute much, if any, information to the pharmacodynamic parameter estimates. As noted, a significant portion of the group 3 effect data represents complete paralysis, and thus the similarity of the pharmacodynamic parameter estimates for group I and 3 patients is particularly encouraging. The actual pharmacodynamic parameter estimates we obtain (Table 11) for dTC are plausible when compared to other available data. The Cpss(SO) of 0.37 ILg/ml is similar to the Cp of O.4S ILg/ml that produced SO% effect in the data of Matteo, Spector, and Horowitz!8 which does not represent steadystate but was obtained while Cp was falling, and so is biased upward relative to our value.
The quantity, keo, characterizes the temporal aspects of drug equilibration with the site of action. If neither drug diffusion from capillary blood to the active site nor delays after drug has occupied the receptor are rate-limiting for the attainment of effect, then keo should be equal to the ratio of the (blood's) perfusion of the tissue containing the active site to the partition coefficient of that tissue. Muscle perfusion is approximately 3 ml/ 100 gm/min while the muscle : blood partition coefficient for dTC has been estimated to be 0.2.7 This results in a theoretical keo of O.IS/min, not substantially different from our value ofO.13/min (Table 11 ).
Because our model is able to characterize the Cp to response relationship despite Cp to active site disequilibrium, it has implications for study design. For example, its use allows one to characterize pharmacodynamics relatively quickly, using non-steady-state and/or nonpseudoequilibrium data. When our data from groups I and 3 were reanalyzed using only the initial 20 to 2S min of data for each patient, the ability to predict the ultimate steady-state effect several hours later, although less than with the complete data set, was, nonetheless, impressive (Fig. S) . The ability to estimate the same sensitivity parameter [Cpss(SO)] as obtained from the complete data was even more impressive (Fig. 6) . This ability to characterize pharmacodynamics quickly may have practical significance in some circumstances. Previously described techniques for gathering dose or Cp and response data and analyzing it for pharmacodynamics either cannot assess dynamics as quickly as our approach permits or suffer from other potential inaccuracies. Exhibiting the former problem is the classical technique involving bolus administration of drug with correlation of Cp and effect as the Cp falls naturally over time. Although relati vely rapid attainment of pseudoequilibrium for dTC makes bias unlikely, if the span of effects from, say, 90% to 10% is to be sampled, the waiting time may be long,22 or even clinically impossible to achieve because of the necessity for further treating the patient. Another type of problem occurs with the Cumulative Dose Response (CDR) curve approach for muscle relaxants, 6 which consists of injecting a small bolus of relaxant, waiting until effect is apparently constant, observing effect, then administering another small bolus, and repeating the process. A plot of cumulative log dose against effect results in an estimate of the dose-response curve. Approximately 5 points on the dose or Cp to response curve can be obtained within 20 to 25 min. This is less than the 15 to 20 points that can be obtained by our approach in an equal period, but that is not the major problem with the CDR technique; rather it is the serious bias possible in the estimated Cp-response relationship. This is because the CDR cannot separate the temporal and sensitivity components of response. Fig. 7 simulates the results of using the CDR technique instead of our approach to assess the Cp to response curve of patients like those in our group 1.
The dark line in Fig. 7 indicates the "true" Cpss to effect relationship one would obtain using the average parameters for group 1 patients (Table I ) and our model. Consider three groups of patients whose Cpss response curves are given by the thick line but who have different forearm perfusion rates (due possibly to different anesthetics' changing the distribution of blood flow/ giving rise to different keo's). One group has a keo 40% of normal, the second, normal, and the third, 160% of normal. Using our model, and the parameters estimated for group 1 patients (Table 11) as the "true" pharmacodynamic relationship, one can calculate the (non-steady-state) Cp and resulting effect one would obtain if the CDR technique were performed, measuring Cp and effect and admin- Table 11 , group I. The "true" curve for all groups as given by our model in terms of steady-state Cp is the dark line. Arrows indicate the predicted Cp(50) for each group: e = 1.1 ILg/ml; 0 = 0.7 ILg/ml; L,. = 0.55 ILg/ml.
istering boluses every 5 min. The three resulting log Cp-response curves for the three groups are shown in Fig. 7 . They are shifted from one another due to varying degrees of disequilibrium, so that the Cp(50) value is apparently different. These are obviously misleading results. One would erroneously conclude that the three groups of patients in the figure should receive different doses to obtain the same effects, yet that would not be true. This raises some question about the appropriateness of the CDR technique. Our approach does not suffer from this problem (see Figs. 5 and 6 ). An additional value of the proposed model in delineating pharmacodynamics is seen in the results for the group 3 patients. When analyzed according to our model, it becomes evident that these results raise the possibility that the doseresponse relationship between renal failure patients and normals may differ (Table Ill) . To confirm this, one would need more data gathered in a fashion similar to that used for group 1 patients. In summary, we present a model for the simultaneous description of pharmacokinetics and pharmacodynamics. We apply it to some data concerning d-tubocurarine. The results verify the necessity of the various components of the model, and its applicability to a wide variety of Cp and effect data, and even allow new conclusions to be suggested upon reanalysis of published data. The limitations of the model include (I) its inability to separately assess the various factors that may contribute to the kinetics of pharmacologic effect (e.g., perfusion, diffusion, partition, and post-receptor events); (2) its assumption that no tolerance to drug effects develops during the period of study (such tolerance has been reported to occur with several drugs 13 ); (3) the requirement that plasma concentrations be measured; and (4) its kinetic simplicity which may cause it to be inadequate to describe complex pharmacodynamics (e.g., Dahlstrom, and co-workers 5 needed a "2-compartment" model for the effect portion alone).
Despite these limitations, the model's advantages are great. These include its ability (I) to separate the temporal and sensitivity components of pharmacodynamics; (2) to use the initial distribution phase of drug administration to characterize a complete dose-response curve accurately; (3) to model extremes of response (0% to 100%), and (4) to provide ample points on the Cp-response curve. While we have studied the application of our model only to dTC which represents an almost ideal case, we believe that this model is equally applicable to the kinetics and dynamics of other drugs.
